These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Verticilide: elucidation of absolute configuration and total synthesis. Monma S; Sunazuka T; Nagai K; Arai T; Shiomi K; Matsui R; Omura S Org Lett; 2006 Nov; 8(24):5601-4. PubMed ID: 17107082 [TBL] [Abstract][Full Text] [Related]
10. Verticilide, a new ryanodine-binding inhibitor, produced by Verticillium sp. FKI-1033. Shiomi K; Matsui R; Kakei A; Yamaguchi Y; Masuma R; Hatano H; Arai N; Isozaki M; Tanaka H; Kobayashi S; Turberg A; Omura S J Antibiot (Tokyo); 2010 Feb; 63(2):77-82. PubMed ID: 20057513 [TBL] [Abstract][Full Text] [Related]
11. Ring Size as an Independent Variable in Cyclooligomeric Depsipeptide Antiarrhythmic Activity. Smith AN; Blackwell DJ; Knollmann BC; Johnston JN ACS Med Chem Lett; 2021 Dec; 12(12):1942-1947. PubMed ID: 34917258 [TBL] [Abstract][Full Text] [Related]
12. EL20, a potent antiarrhythmic compound, selectively inhibits calmodulin-deficient ryanodine receptor type 2. Klipp RC; Li N; Wang Q; Word TA; Sibrian-Vazquez M; Strongin RM; Wehrens XHT; Abramson JJ Heart Rhythm; 2018 Apr; 15(4):578-586. PubMed ID: 29248564 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia. Hwang HS; Hasdemir C; Laver D; Mehra D; Turhan K; Faggioni M; Yin H; Knollmann BC Circ Arrhythm Electrophysiol; 2011 Apr; 4(2):128-35. PubMed ID: 21270101 [TBL] [Abstract][Full Text] [Related]
14. RYR2 Channel Inhibition Is the Principal Mechanism of Flecainide Action in CPVT. Kryshtal DO; Blackwell DJ; Egly CL; Smith AN; Batiste SM; Johnston JN; Laver DR; Knollmann BC Circ Res; 2021 Feb; 128(3):321-331. PubMed ID: 33297863 [TBL] [Abstract][Full Text] [Related]
15. A potent and selective cis-amide inhibitor of ryanodine receptor 2 as a candidate for cardiac arrhythmia treatment. Ishida R; Kurebayashi N; Iinuma H; Zeng X; Mori S; Kodama M; Murayama T; Masuno H; Takeda F; Kawahata M; Tanatani A; Miura A; Nishio H; Sakurai T; Kagechika H Eur J Med Chem; 2023 Dec; 262():115910. PubMed ID: 37922828 [TBL] [Abstract][Full Text] [Related]
16. Enhanced Cytosolic Ca2+ Activation Underlies a Common Defect of Central Domain Cardiac Ryanodine Receptor Mutations Linked to Arrhythmias. Xiao Z; Guo W; Sun B; Hunt DJ; Wei J; Liu Y; Wang Y; Wang R; Jones PP; Back TG; Chen SRW J Biol Chem; 2016 Nov; 291(47):24528-24537. PubMed ID: 27733687 [TBL] [Abstract][Full Text] [Related]
17. Phenytoin Reduces Activity of Cardiac Ryanodine Receptor 2; A Potential Mechanism for Its Cardioprotective Action. Ashna A; van Helden DF; Dos Remedios C; Molenaar P; Laver DR Mol Pharmacol; 2020 Apr; 97(4):250-258. PubMed ID: 32015008 [TBL] [Abstract][Full Text] [Related]
18. The central domain of cardiac ryanodine receptor governs channel activation, regulation, and stability. Guo W; Sun B; Estillore JP; Wang R; Chen SRW J Biol Chem; 2020 Nov; 295(46):15622-15635. PubMed ID: 32878990 [TBL] [Abstract][Full Text] [Related]
19. Screening for Novel Type 2 Ryanodine Receptor Inhibitors by Endoplasmic Reticulum Ca Takenaka M; Kodama M; Murayama T; Ishigami-Yuasa M; Mori S; Ishida R; Suzuki J; Kanemaru K; Sugihara M; Iino M; Miura A; Nishio H; Morimoto S; Kagechika H; Sakurai T; Kurebayashi N Mol Pharmacol; 2023 Dec; 104(6):275-286. PubMed ID: 37678938 [TBL] [Abstract][Full Text] [Related]
20. RyR2 disease mutations at the C-terminal domain intersubunit interface alter closed-state stability and channel activation. Guo W; Wei J; Estillore JP; Zhang L; Wang R; Sun B; Chen SRW J Biol Chem; 2021 Jul; 297(1):100808. PubMed ID: 34022226 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]